journal article
Open Access
Mar 22, 2016
Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions
Topics
No keywords indexed for this article. Browse by subject →
References
106
[1]
IDF Diabetes Atlas 2014. Available at http://www.idf.org/diabetesatlas/update-2014.
[2]
Leslie WD, Rubin MR, Schwartz AV et al. Type 2 diabetes and bone. J Bone Miner Res 2012; 27: 2231–2237.
10.1002/jbmr.1759
[3]
Schwartz AV, Sellmeyer DE, Ensrud KE et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001; 86: 32–38.
10.1210/jcem.86.1.7139
[4]
Bonds DE, Larson JC, Schwartz AV et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006; 91: 3404–3410.
10.1210/jc.2006-0614
[5]
Janghorbani M, Van Dam RM, Willett WC et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166: 495–505.
10.1093/aje/kwm106
[6]
Leslie WD, Lix LM, Prior HJ et al. Biphasic fracture risk in diabetes: a population-based study. Bone 2007; 40: 1595–1601.
10.1016/j.bone.2007.02.021
[7]
de Liefde II, van der Klift M, de Laet CE et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam study. Osteoporos Int 2005; 16: 1713–1720.
10.1007/s00198-005-1909-1
[8]
Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis
P. Vestergaard
Osteoporosis International
2007
10.1007/s00198-006-0253-4
[9]
Giangregorio LM, Leslie WD, Lix LM et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 2012; 27: 301–308.
10.1002/jbmr.556
[10]
Leslie WD, Morin SN, Lix LM et al. Does diabetes modify the effect of FRAX risk factors for predicting major osteoporotic and hip fracture? Osteoporos Int 2014; 25: 2817–2824.
10.1007/s00198-014-2822-2
[11]
Schwartz AV, Hillier TA, Sellmeyer DE et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002; 25: 1749–1754.
10.2337/diacare.25.10.1749
[12]
Loke YK, Singh S, Furberg CD . Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32–39.
10.1503/cmaj.080486
[13]
Dobnig H, Piswanger-Solkner JC, Roth M et al. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab 2006; 91: 3355–3363.
10.1210/jc.2006-0460
[14]
Ardawi MS, Akhbar DH, Alshaikh A et al. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone 2013; 56: 355–362.
10.1016/j.bone.2013.06.029
[15]
Yamamoto M, Yamaguchi T, Nawata K et al. Decreased PTH levels accompanied by low-bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 1277–1284.
10.1210/jc.2011-2537
[16]
Gaudio A, Privitera F, Battaglia K et al. Sclerostin levels associated with inhibition of the WNT/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97: 3744–3750.
10.1210/jc.2012-1901
[17]
Krakauer JC, McKenna MJ, Buderer NF et al. Bone loss and bone turnover in diabetes. Diabetes 1995; 44: 775–782.
10.2337/diab.44.7.775
[18]
Manavalan JS, Cremers S, Dempster DW et al. Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97: 3240–3250.
10.1210/jc.2012-1546
[19]
Kanazawa I, Yamaguchi T, Sugimoto T . Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 2011; 22: 1191–1198.
10.1007/s00198-010-1310-6
[20]
Eghbali-Fatourechi GZ, Modder UI, Charatcharoenwitthaya N et al. Characterization of circulating osteoblast lineage cells in humans. Bone 2007; 40: 1370–1377.
10.1016/j.bone.2006.12.064
[21]
Rubin MR, Manavalan JS, Dempster DW et al. Parathyroid hormone stimulates circulating osteogenic cells in hypoparathyroidism. J Clin Endocrinol Metab 2011; 96: 176–186.
10.1210/jc.2009-2682
[22]
Ardawi M, Akbar D, Rouzi A et al. Elevated sphingosine 1-phosphate levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Bone Miner Res 2014; 29 Suppl 1. Available at http://www.asbmr.org/education/AbstractDetail?aid=51ef5a65-8072-4369-b2b7-c1381053da59. 11 December 2014.
[23]
Saito M, Fujii K, Mori Y et al. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006; 17: 1514–1523.
10.1007/s00198-006-0155-5
[24]
Khosravi R, Sodek KL, Faibish M et al. Collagen advanced glycation inhibits its discoidin domain receptor 2 (DDR2)-mediated induction of lysyl oxidase in osteoblasts. Bone 2014; 58: 33–41.
10.1016/j.bone.2013.10.001
[25]
Canalis E . Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol 2013; 9: 575–583.
10.1038/nrendo.2013.154
[26]
Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97: 234–241.
10.1210/jc.2011-2186
[27]
Gennari L, Merlotti D, Valenti R et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 1737–1744.
10.1210/jc.2011-2958
[28]
Yamamoto M, Yamauchi M, Sugimoto T . Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013; 98: 4030–4037.
10.1210/jc.2013-2143
[29]
Heilmeier U, Carpenter DR, Patsch JM et al. Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures. Osteoporos Int 2015; 26: 1283–1293.
10.1007/s00198-014-2988-7
[30]
Tang SY, Allen MR, Phipps R et al. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009; 20: 887–894.
10.1007/s00198-008-0754-4
[31]
Morales-Santana S, Garcia-Fontana B, Garcia-Martin A et al. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care 2013; 36: 1667–1674.
10.2337/dc12-1691
[32]
Frye EB, Degenhardt TP, Thorpe SR et al. Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J Biol Chem 1998; 273: 18714–18719.
10.1074/jbc.273.30.18714
[33]
Monnier VM, Sell DR, Genuth S . Glycation products as markers and predictors of the progression of diabetic complications. Ann NY Acad Sci 2005; 1043: 567–581.
10.1196/annals.1333.065
[34]
Thornalley PJ, Langborg A, Minhas HS . Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999; 344 Pt 1: 109–116.
10.1042/bj3440109
[35]
Makita Z, Radoff S, Rayfield EJ et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836–842.
10.1056/nejm199109193251202
[36]
Brownlee M, Cerami A, Vlassara H . Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315–1321.
10.1056/nejm198805193182007
[37]
Vashishth D . The role of the collagen matrix in skeletal fragility. Curr Osteoporos Rep 2007; 5: 62–66.
10.1007/s11914-007-0004-2
[38]
Schwartz AV, Garnero P, Hillier TA et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 2380–2386.
10.1210/jc.2008-2498
[39]
Sanguineti R, Storace D, Monacelli F et al. Pentosidine effects on human osteoblasts in vitro. Ann NY Acad Sci 2008; 1126: 166–172.
10.1196/annals.1433.044
[40]
McCarthy AD, Uemura T, Etcheverry SB et al. Advanced glycation endproducts interefere with integrin-mediated osteoblastic attachment to a type-I collagen matrix. Int J Biochem Cell Biol 2004; 36: 840–848.
10.1016/j.biocel.2003.09.006
[41]
McCarthy AD, Etcheverry SB, Cortizo AM . Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development. Acta Diabetol 2001; 38: 113–122.
10.1007/s005920170007
[42]
Kume S, Kato S, Yamagishi S et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 2005; 20: 1647–1658.
10.1359/jbmr.050514
[43]
Valcourt U, Merle B, Gineyts E et al. Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem 2007; 282: 5691–5703.
10.1074/jbc.m610536200
[44]
Zhang L, Chen B, Tang L . Metabolic memory: mechanisms and implications for diabetic retinopathy. Diabetes Res Clin Pract 2012; 96: 286–293.
10.1016/j.diabres.2011.12.006
[45]
Genuth S, Sun W, Cleary P et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005; 54: 3103–3111.
10.2337/diabetes.54.11.3103
[46]
Diagnosis of osteoporosis and assessment of fracture risk
John A Kanis
The Lancet
2002
10.1016/s0140-6736(02)08761-5
[47]
Link TM . Osteoporosis imaging: state of the art and advanced imaging. Radiology 2012; 263: 3–17.
10.1148/radiol.12110462
[48]
Schwartz AV, Vittinghoff E, Bauer DC et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011; 305: 2184–2192.
10.1001/jama.2011.715
[49]
Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: Applications in the study of human trabecular bone microarchitecture
Laurent Pothuaud, Pascal Carceller, Didier Hans
Bone
2008
10.1016/j.bone.2007.11.018
[50]
Harvey NC, Gluer CC, Binkley N et al. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone 2015; 78: 216–224.
10.1016/j.bone.2015.05.016
Showing 50 of 106 references
Metrics
103
Citations
106
References
Details
- Published
- Mar 22, 2016
- Vol/Issue
- 4(1)
- License
- View
Authors
Cite This Article
Mishaela R Rubin, Janina M Patsch (2016). Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions. Bone Research, 4(1). https://doi.org/10.1038/boneres.2016.1
Related
You May Also Like
TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease
Mengrui Wu, Guiqian Chen · 2016
1,419 citations
Bone Regeneration Based on Tissue Engineering Conceptions — A 21st Century Perspective
Jan Henkel, Maria A. Woodruff · 2013
802 citations
Paracrine and endocrine actions of bone—the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts
Yujiao Han, Xiuling You · 2018
479 citations
Evolving concepts in bone infection: redefining “biofilm”, “acute vs. chronic osteomyelitis”, “the immune proteome” and “local antibiotic therapy”
Elysia A. Masters, Ryan P. Trombetta · 2019
468 citations